Trials / Recruiting
RecruitingNCT07230860
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-95597528 | JNJ-95597528 will be administered subcutaneously. |
| DRUG | Placebo | Placebo will be administered subcutaneously. |
Timeline
- Start date
- 2026-01-20
- Primary completion
- 2026-11-19
- Completion
- 2028-02-10
- First posted
- 2025-11-17
- Last updated
- 2026-04-13
Locations
52 sites across 7 countries: United States, Argentina, Brazil, Canada, China, Japan, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07230860. Inclusion in this directory is not an endorsement.